loading

PAGE IS LOADING

Orthocell's Journey in Regenerative Medicine

An ASX-listed company at the forefront of regenerative medicine in Australia, serving a broad patient population through world-leading therapeutic products.


Story: Regenerating Hope – Orthocell's Journey in Australian Regenerative Medicine
Episode: 1
Presenter: Chrissy Morrisy
Air Date: 7th April 2024


An ASX-listed company at the forefront of regenerative medicine in Australia, serving a broad patient population through world-leading therapeutic products.

  • "Regenerative Medicine," an emerging field, focuses on leveraging the body's natural capacity to repair and replace damaged tissue. Orthocell, a biotech company located in Western Australia, has garnered widespread attention for its advancements in this domain.
  • Their primary focus lies in developing technology aimed at regenerating damaged or severed nerves, potentially offering a ray of hope for individuals suffering from paralysis by restoring movement to affected limbs.
  • This innovative blend of biotechnology and surgical intervention has benefited over 20 patients in Perth, marking a significant departure from conventional treatment approaches.
  • Emplir stands out as one of Orthocell's flagship products, representing the outcome of a ten-year journey of research and development. Notably, Emplir's design prioritizes ease of use, making it relatively simple for surgeons to undergo training and adopt it into their practice seamlessly.
  • Chrissy queries Paul about the development and future prospects of Remplir within the realm of biotechnology. Paul outlines Remplir's developmental journey, spanning from bench testing with DNA to its current application in restoring limb function in humans, including nerve transfers.

For more information, head to:
https://orthocell.com/

More From This Episode